These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 32415847)
61. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004 [TBL] [Abstract][Full Text] [Related]
62. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia]. Samalin L; Ben Gharbia M; Garnier M; Llorca PM Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735 [TBL] [Abstract][Full Text] [Related]
63. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. Borison RL; Arvanitis LA; Miller BG J Clin Psychopharmacol; 1996 Apr; 16(2):158-69. PubMed ID: 8690831 [TBL] [Abstract][Full Text] [Related]
64. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. Gunasekara NS; Spencer CM; Keating GM CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335 [TBL] [Abstract][Full Text] [Related]
65. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Puech A; Fleurot O; Rein W Acta Psychiatr Scand; 1998 Jul; 98(1):65-72. PubMed ID: 9696517 [TBL] [Abstract][Full Text] [Related]
66. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Leucht S; Corves C; Arbter D; Engel RR; Li C; Davis JM Lancet; 2009 Jan; 373(9657):31-41. PubMed ID: 19058842 [TBL] [Abstract][Full Text] [Related]
67. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. Masuda T; Misawa F; Takase M; Kane JM; Correll CU JAMA Psychiatry; 2019 Oct; 76(10):1052-1062. PubMed ID: 31365048 [TBL] [Abstract][Full Text] [Related]
68. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950 [TBL] [Abstract][Full Text] [Related]
69. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Oya K; Kishi T; Iwata N Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702 [TBL] [Abstract][Full Text] [Related]
70. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Stip E; Tourjman V Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550 [TBL] [Abstract][Full Text] [Related]
71. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505 [TBL] [Abstract][Full Text] [Related]
72. Paliperidone extended release: a review of its use in the management of schizophrenia. Chwieduk CM; Keating GM Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835 [TBL] [Abstract][Full Text] [Related]
73. Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-analysis. Tonin FS; Piazza T; Wiens A; Fernandez-Llimos F; Pontarolo R Schizophr Res; 2015 Dec; 169(1-3):483-485. PubMed ID: 26516102 [TBL] [Abstract][Full Text] [Related]
74. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Casey DE; Sands EE; Heisterberg J; Yang HM Psychopharmacology (Berl); 2008 Oct; 200(3):317-31. PubMed ID: 18597078 [TBL] [Abstract][Full Text] [Related]
75. Pimozide for schizophrenia or related psychoses. Mothi M; Sampson S Cochrane Database Syst Rev; 2013 Nov; (11):CD001949. PubMed ID: 24194433 [TBL] [Abstract][Full Text] [Related]
76. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720 [TBL] [Abstract][Full Text] [Related]
78. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. Lin CH; Wang FC; Lin SC; Huang YH; Chen CC; Lane HY Int Clin Psychopharmacol; 2013 Sep; 28(5):267-74. PubMed ID: 23778382 [TBL] [Abstract][Full Text] [Related]
79. Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia. Yoshida K; Takeuchi H Behav Brain Res; 2021 Mar; 402():113098. PubMed ID: 33417992 [TBL] [Abstract][Full Text] [Related]
80. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. Harvey RC; James AC; Shields GE CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]